[CAS NO. 1973403-00-7]  ARCC-4

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1973403-00-7]

Catalog
AS971633
Brand
Arctom Scientific
CAS
1973403-00-7

DESCRIPTION [1973403-00-7]

Overview

MDL-
Molecular Weight1024.18
Molecular FormulaC53H56F3N7O7S2
SMILESO=C(NCC1=CC=C(C2=C(C)N=CS2)C=C1)[C@H]3N(C([C@H](C(C)(C)C)NC(COCCCCOC4=CC=C(C5=CC=C(N(C(N6C7=CC=C(C#N)C(C(F)(F)F)=C7)=S)C(C)(C)C6=O)C=C5)C=C4)=O)=O)C[C@H](O)C3

For research use only. We do not sell to patients.

Summary

ARCC-4 is a low-nanomolar Androgen Receptor (AR) degrader based on PROTAC , with a DC 50 of 5 nM. ARCC-4 is an enzalutamide-based von Hippel-Lindau (VHL)-recruiting AR PROTAC and outperforms enzalutamide. ARCC-4 effectively degrades clinically relevant AR mutants associated with antiandrogen therapy [1] .


IC50 & Target

VHL


In Vitro

ARCC-4 induces apoptosis and inhibiting proliferation of AR-amplified prostate cancer cells [1] .
ARCC-4 enhances protein-protein interactions between AR and VHL, thereby promoting the association of the trimeric complex [1] .
ARCC-4 (0.1-10,000 nM; 20 hours) potently degrades AR with a D 50 of 5 nM and D max of over 95% [1] .
ARCC-4 (100 nM; 12 hours) shows near complete AR degradation (>98%) in prostate cancer cells [1] .
ARCC-4 selectively degrades AR via the proteasome but not PR-A or PR-B suppression [1] .
ARCC-4 shows efficacy against clinically relevant AR mutations [1] .
ARCC-4 maintains activity despite elevated androgen levels [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis [1]

Cell Line: VCaP cells
Concentration: 0.1 nM, 1 nM, 10 nM, 50 nM, 100 nM, 0.5μM, 1μM, 10 μM
Incubation Time: 20 hours
Result: Potently degrades AR

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 200 mg/mL ( 195.28 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.9764 mL 4.8820 mL 9.7639 mL
5 mM 0.1953 mL 0.9764 mL 1.9528 mL
10 mM 0.0976 mL 0.4882 mL 0.9764 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: 5 mg/mL (4.88 mM); Suspended solution; Need ultrasonic

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: 5 mg/mL (4.88 mM); Suspended solution; Need ultrasonic

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 5 mg/mL (4.88 mM); Clear solution

* All of the co-solvents are available by MCE.